TY - JOUR
T1 - Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens
T2 - A preliminary report
AU - Hourvitz, A.
AU - Mosseri, R.
AU - Solomon, A.
AU - Yehezkelli, Y.
AU - Atsmon, J.
AU - Danon, Y. L.
AU - Koren, R.
AU - Shouval, D.
PY - 1996/1
Y1 - 1996/1
N2 - A new vaccine against hepatitis B virus (HBV) infection, produced in mammalian Chinese hamster ovary (CHO) cells, contains the small (s), middle (Pre S2) and large (Pre S1) surface proteins of HBV. Three injections of a 5-μg or 10-μg dose were administered intramuscularly (i.m.) at 0, 1 and 6 months to a group of 105 young adults, who were monitored for a period of 6 months after the third injection. Seroconversion rates were 100% after the second injection of the 5-μg or 10-μg dose. Geometric mean titres of HBsAb at 1 month after the third injection were 12 156 mIU ml-1 and 13 482 mIU ml-1 in those receiving the 5-μg and 10-μg dose respectively. The vaccine was well tolerated with no significant adverse events. These preliminary results suggest that the Pre S-s recombinant vaccine, produced in mammalian cells, is highly immunogenic, leading to 100% seroconversion in the population tested after injection of only two doses of 5 μg.
AB - A new vaccine against hepatitis B virus (HBV) infection, produced in mammalian Chinese hamster ovary (CHO) cells, contains the small (s), middle (Pre S2) and large (Pre S1) surface proteins of HBV. Three injections of a 5-μg or 10-μg dose were administered intramuscularly (i.m.) at 0, 1 and 6 months to a group of 105 young adults, who were monitored for a period of 6 months after the third injection. Seroconversion rates were 100% after the second injection of the 5-μg or 10-μg dose. Geometric mean titres of HBsAb at 1 month after the third injection were 12 156 mIU ml-1 and 13 482 mIU ml-1 in those receiving the 5-μg and 10-μg dose respectively. The vaccine was well tolerated with no significant adverse events. These preliminary results suggest that the Pre S-s recombinant vaccine, produced in mammalian cells, is highly immunogenic, leading to 100% seroconversion in the population tested after injection of only two doses of 5 μg.
KW - Hepatitis B
KW - Mammalian cell vaccine
KW - Pre S proteins
UR - http://www.scopus.com/inward/record.url?scp=0029687236&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2893.1996.tb00079.x
DO - 10.1111/j.1365-2893.1996.tb00079.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 8736239
AN - SCOPUS:0029687236
SN - 1352-0504
VL - 3
SP - 37
EP - 42
JO - Journal of Viral Hepatitis
JF - Journal of Viral Hepatitis
IS - 1
ER -